[{"data":1,"prerenderedAt":587},["ShallowReactive",2],{"uc-digital-pathology-cancer-detection":3,"uc-regulations":355},{"useCase":4,"evidence":176,"blitsAiDeployments":247,"benchmarks":248,"indicative":254,"related":257,"indexability":353,"includeUnpublished":182},{"title":5,"shortTitle":6,"seoTitle":7,"metaDescription":8,"status":9,"definition":10,"aliases":11,"industries":16,"functions":18,"patterns":20,"channels":23,"audience":25,"autonomy":26,"adoptionStage":27,"problem":28,"problemStats":29,"howItWorks":30,"valueDrivers":31,"kpis":35,"indicativeValue":39,"macroEstimates":73,"feasibility":74,"implementation":85,"risk":123,"blitsAi":153,"faq":155,"related":168,"datePublished":171,"dateModified":171,"lastVerified":171,"changelog":172,"slug":175},"AI cancer detection in digital pathology slides","Digital pathology cancer detection","AI cancer detection in digital pathology","AI that reviews scanned biopsy slides and flags cancer for the pathologist. UTMB reports 30% shorter turnaround and 38% less immunohistochemistry in biopsies.","published","AI cancer detection in digital pathology is software that analyzes scanned biopsy slides, marks areas likely to contain cancer, suggests a grade and prompts a second look or reorders the worklist. A pathologist reviews the slides and signs every report.",[12,13,14,15],"AI prostate biopsy pathology","computational pathology cancer detection","AI second read for pathology","whole slide image AI",[17],"healthcare",[19],"operations",[21,22],"computer-vision","prediction-and-scoring",[24],"internal-tools","employee-facing","copilot","early-adopters","A prostate biopsy can produce a dozen or more tissue cores on several slides, and the pathologist has to find\nsmall foci of cancer among mostly benign tissue, grade them and decide whether to order extra stains. Missed or undergraded foci\nchange treatment, and many laboratories also order immunohistochemistry (IHC) stains to confirm borderline findings, which adds cost and days\nto the result. Pathologist capacity is short in many health systems while biopsy volumes keep rising.\n\nOnce a laboratory scans its slides, software can read the whole slide image. The deployments on this page use it for prostate biopsies, where\napproved products exist. In Articulate Pro, three NHS centres used it as a second read or a concurrent read, and the University of Texas Medical Branch (UTMB) built it into\nroutine sign out. The software does not issue a diagnosis. It raises a flag, a pathologist decides, and the evidence so far shows\nfewer unnecessary stains and shorter turnaround, with a small number of diagnosis changes that need the pathologist's judgment.",[],"1. **Scan the slides.** The laboratory digitizes the glass slides on a whole slide scanner and sends the images to the AI product through the\n   pathology image management system.\n2. **Analyze each slide.** The model marks areas suspicious for cancer, gives a probability per slide or per case and, depending on the product, suggests a\n   grade group and flags features such as perineural invasion.\n3. **Show the result to the pathologist.** In a second read workflow the pathologist reads first, and the system prompts a review where its view differs.\n   In a concurrent read workflow the pathologist sees the marks from the start.\n4. **Decide and sign.** The pathologist decides on additional cuts, stains or a second opinion and signs the report. The AI never reports a diagnosis by itself.\n5. **Monitor.** The laboratory tracks discrepancies between the AI and the pathologist, turnaround time and stain use, and checks performance after any change to a scanner or staining protocol.",[32,33,34],"employee-productivity","speed","risk-reduction",[36,37,38],"processing-time-reduction","detection-rate-improvement","productivity-gain",{"referenceOrg":40,"inputs":41,"formula":68,"currency":69,"period":70,"resultLabel":71,"caveat":72},"A pathology laboratory that reports 5,000 prostate biopsy cases a year",[42,47,54,61],{"key":43,"label":44,"low":45,"high":45,"unit":43,"note":46},"cases","Prostate biopsy cases per year",5000,"The reference laboratory.",{"key":48,"label":49,"low":50,"high":51,"unit":52,"note":53},"stainsPerCase","IHC stains ordered per case before AI",1,3,"stains per case","Editorial assumption, replace with your own order data.",{"key":55,"label":56,"low":57,"high":58,"unit":59,"note":60},"stainReduction","Share of IHC stains avoided",0.15,0.3,"fraction of stains","Below the figure on this page (UTMB reports 38% lower IHC utilization after implementation, in a before and after comparison of 139 cases).",{"key":62,"label":63,"low":64,"high":65,"unit":66,"note":67},"costPerStain","Cost of one IHC stain, reagent and technician time",20,60,"USD per stain","Editorial assumption, replace with your own laboratory cost.","cases * stainsPerCase * stainReduction * costPerStain","USD","per year","Annual IHC cost avoided","Gross stain cost only. It leaves out the license and integration cost of the AI product and the scanner, the cost of pathologist review time spent on AI flags, and the value of shorter turnaround and of cancers found earlier.",[],{"complexity":75,"complexityNote":76,"dataPrerequisites":77,"integrations":81},"high","The laboratory needs a fully digital workflow first: whole slide scanners, an image management system and storage for large images. The AI product is a regulated diagnostic device bought from a vendor, so the build is the connection to the image system and laboratory information system, a local validation on the laboratory's own slides and stains, and a written sign out protocol.",[78,79,80],"Consecutive prostate biopsy cases scanned in the laboratory's own workflow, with the final pathologist diagnoses as ground truth","Records of IHC orders, second opinions and turnaround time before the AI to compare against","Scanner and stain settings documented, since performance can change when they change",[82,83,84],"Whole slide scanner and pathology image management system","Laboratory information system for orders, results and sign out","Pathologist viewing workstation, so the AI marks display during the read",{"steps":86,"guardrails":102,"humanInTheLoop":107,"kpisToInstrument":108,"failureModes":113},[87,90,93,96,99],{"title":88,"detail":89},"Digitize the workflow","Scan all cases of the target type before any AI is added, so turnaround and stain use can be measured as a baseline.",{"title":91,"detail":92},"Validate on your own slides","Run the product on consecutive past cases with known diagnoses and compare sensitivity and specificity with the vendor's claims. Repeat on a sample from each scanner.",{"title":94,"detail":95},"Choose second read or concurrent read","Start with the AI as a second read after the pathologist's first view, then move to concurrent reading where the evidence supports it. Write the protocol for what happens when the AI and the pathologist disagree.",{"title":97,"detail":98},"Run a prospective period","Report a defined set of cases with the AI, record every change to the diagnosis or grade, and compare turnaround and stain use with unassisted cases.",{"title":100,"detail":101},"Monitor performance","Review discrepancies each quarter and after any change to the scanner, the staining protocol or the patient mix.",[103,104,105,106],"A pathologist reviews and signs every case, and the AI never issues a report","The AI runs only for the case types and scanners it was validated on","Local validation is repeated after a scanner, stain or software change","The laboratory tracks disagreement cases and reviews them with a second pathologist","Pathologists read every slide and own the diagnosis and the decision to order more stains. The laboratory director owns the validation, the sign out protocol and the monitoring of discrepancies.",[109,110,111,112],"Turnaround time from scan completion to sign out, with and without AI","IHC stains per case and second opinions requested","Share of cases where the AI prompted a change to the diagnosis or grade, and the outcome on review","Disagreement between AI and pathologist by case type and scanner",[114,117,120],{"title":115,"detail":116},"Domain shift","A model trained on one scanner, stain or population performs differently on another. A 2026 practice review of the two FDA cleared prostate products stresses domain shift and the risk of unequal performance in under represented patients, and says clearance must be followed by local validation and ongoing monitoring.",{"title":118,"detail":119},"Pathologists over trust the flag","A reader who accepts a negative AI result stops looking for small foci. Use the second read order for new users and audit a sample of cases the AI marked benign.",{"title":121,"detail":122},"Alert fatigue","A model with high sensitivity and lower specificity flags benign tissue and adds review work. Track the false positive flags per case and adjust the workflow, not only the model.",{"euAiAct":124,"regulations":126,"guidance":130,"controls":147,"incidents":152},{"tier":75,"basis":125},"Article 6(1) with Annex I: an AI system that is an in vitro diagnostic device under Regulation (EU) 2017\u002F746, or a safety component of one, is high risk when the device needs a third party conformity assessment. Software that analyzes slides to support a cancer diagnosis is normally classified in a class that needs a notified body, so it carries the AI Act duties for risk management, data governance, logging and human oversight on top of the device route. It is not an Annex III use. Laboratories that build and use a device only inside their own health institution can fall under the in house exemption of Article 5(5) of that regulation.",[127,128,129],"eu-ai-act","gdpr","hipaa",[131,137,141],{"title":132,"issuer":133,"region":134,"url":135,"note":136},"Regulation (EU) 2024\u002F1689, Article 6 and Annex I, classification rules for high risk AI systems","European Union","europe","https:\u002F\u002Feur-lex.europa.eu\u002Feli\u002Freg\u002F2024\u002F1689\u002Foj","An AI system that is a medical device or an in vitro diagnostic device, or a safety component of one, is high risk when a third party conformity assessment is required.",{"title":138,"issuer":133,"region":134,"url":139,"note":140},"Regulation (EU) 2017\u002F746 on in vitro diagnostic medical devices","https:\u002F\u002Feur-lex.europa.eu\u002Feli\u002Freg\u002F2017\u002F746\u002Foj","Sets the classification and conformity assessment route for diagnostic software that analyzes specimens.",{"title":142,"issuer":143,"region":144,"url":145,"note":146},"Artificial Intelligence in Digital Pathology for Prostate Cancer Detection, FDA Clearance and Real World Implementation (Journal of Clinical Pathology, 2026)","Journal of Clinical Pathology","global","https:\u002F\u002Fwww.ebi.ac.uk\u002Feuropepmc\u002Fwebservices\u002Frest\u002Fsearch?query=EXT_ID:42468971&resultType=core&format=json","Practice oriented review of the two FDA cleared prostate biopsy AI tools. It covers domain shift, unequal performance in under represented patients and the need for local validation and ongoing monitoring.",[148,149,150,151],"Documented local validation on the laboratory's own scanners, stains and case mix before any reporting use","Written sign out protocol that states the AI is a second reader and who decides on a disagreement","Audit trail that shows the AI output, the pathologist and the final diagnosis per case","Scheduled review of discrepancies and of performance after any change to scanner or stain",[],{"howToBuild":154},"The image analysis is done by a certified pathology AI product, and Blits.ai does not read slides or score cases. Blits.ai works around the laboratory's\nprocess. An **agent** with a **knowledge base** of the sign out protocol, validation reports and standard operating procedures answers staff questions on\nwhen the AI runs and what to do on a disagreement, and a **SQL knowledge base** on the laboratory's audit tables lets the director ask for turnaround time, stain use and\ndiscrepancy counts in plain language.\n\nFor clinicians and patients, an agent on **web chat or voice** can answer questions about the status of a biopsy result and the next appointment, with **flows** and **custom functions** that read\nthe booking system and **human handover** to a nurse or clinic for anything clinical. **Test suites** keep answers stable after each change, and **guardrails** and\n**PII masking** keep patient identifiers out of prompts. Run Blits.ai in our cloud in the EU, Qatar, Singapore, the UAE, the US or Australia, in your private cloud, or fully on premises.",[156,159,162,165],{"question":157,"answer":158},"Does AI replace the pathologist who reads a biopsy?","In the deployments on this page it does not. In the Articulate Pro study at three NHS centres the AI assisted the histopathologist, and UTMB states that the pathologist keeps responsibility for the final diagnosis. The software flags and grades, and the pathologist signs the report.",{"question":160,"answer":161},"How often does AI change a prostate biopsy diagnosis?","In the Articulate Pro study, staged AI assistance as a second read changed the initial diagnosis or Grade Group in 21 of 386 patients (5.4%), and 5 of them (1.3%) could affect clinical management. The study reports the changes and does not call every one an error corrected.",{"question":163,"answer":164},"What does AI do to turnaround time in pathology?","UTMB reports a 30% shorter diagnostic turnaround and 38% less IHC use after implementation, in a small before and after comparison of 139 cases. Articulate Pro reports a mean reduction of 30.1 hours with concurrent reading at one of three sites. The sites differ, so measure your own baseline.",{"question":166,"answer":167},"Is pathology AI high risk under the EU AI Act?","Usually yes. Software that analyzes slides to support a cancer diagnosis is an in vitro diagnostic device that needs a notified body, which puts it in the high risk tier through Article 6(1) and Annex I. The vendor carries the conformity work, and the laboratory carries the duties of a deployer.",[169,170],"breast-cancer-screening-mammography-reading","radiology-worklist-triage","2026-11-18",[173],{"date":171,"note":174},"First published","digital-pathology-cancer-detection",[177,220],{"title":178,"useCases":179,"organization":180,"vendors":186,"summary":190,"stage":191,"year":192,"channels":193,"languages":194,"metrics":196,"outcomeDisclosed":206,"sources":207,"verification":215,"grade":217,"id":218,"organizationSlug":219},"University of Texas Medical Branch: AI assisted prostate biopsy sign out",[175],{"name":181,"anonymized":182,"country":183,"region":184,"industry":17,"wikidata":185},"The University of Texas Medical Branch",false,"US","north-america","Q921264",[187],{"name":188,"role":189},"Ibex Medical Analytics","platform","The Department of Pathology at the University of Texas Medical Branch in Galveston validated an AI assisted prostate biopsy decision support tool on routine cases within its fully digital practice and then put it into routine sign out. The validation met all predefined acceptance criteria. A before and after comparison of three month periods found shorter diagnostic turnaround and less use of immunohistochemistry, with the pathologist keeping responsibility for the diagnosis.","production",2024,[24],[195],"en",[197],{"kpi":36,"value":198,"unit":199,"qualifier":200,"period":201,"baseline":202,"claimant":203,"quote":204,"sourceUrl":205},30,"percent","exact","Diagnostic turnaround time, three months after implementation against three months before","Prostate biopsy sign out before the AI tool","organization","Following clinical implementation, diagnostic TAT decreased by 30% and IHC utilization decreased by 38%.","https:\u002F\u002Fwww.ebi.ac.uk\u002Feuropepmc\u002Fwebservices\u002Frest\u002Fsearch?query=EXT_ID:42245328&resultType=core&format=json",true,[208,212],{"url":205,"title":209,"publisher":210,"date":211},"Validation, implementation, and impact of an AI model in routine practice for pathologic diagnosis of prostate cancer in an academic medical center (abstract via Europe PMC)","Journal of Pathology Informatics","2026-05-09",{"url":213,"title":214,"publisher":210,"date":211},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC13231069\u002F","Validation, implementation, and impact of an AI model in routine practice for pathologic diagnosis of prostate cancer in an academic medical center",{"level":216,"checkedAt":171},"source-verified","B","university-of-texas-medical-branch-ibex-prostate-biopsy-sign-out",null,{"title":221,"useCases":222,"organization":223,"vendors":227,"summary":230,"stage":231,"year":232,"channels":233,"languages":234,"metrics":235,"outcomeDisclosed":206,"sources":236,"verification":245,"grade":217,"id":246,"organizationSlug":219},"Oxford University Hospitals and two other NHS trusts: Articulate Pro prospective study of AI assisted prostate biopsy reporting",[175],{"name":224,"anonymized":182,"country":225,"region":134,"industry":17,"wikidata":226},"Oxford University Hospitals NHS Foundation Trust","GB","Q16976147",[228],{"name":229,"role":189},"Paige","Three NHS specialist centres in England, led from the University of Oxford and Oxford University Hospitals, reported prostate biopsies in routine care with a commercially available AI system (Paige Prostate) alongside the histopathologist. Of 1,613 cases, 1,049 were reported with AI assistance, either as a second read after the initial diagnosis or as a concurrent read from the start. The study measured changes to diagnosis, effect on patient management and turnaround time, and the pathologist signed every report.","pilot",2022,[24],[195],[],[237,242],{"url":238,"title":239,"publisher":240,"date":241},"https:\u002F\u002Fwww.ebi.ac.uk\u002Feuropepmc\u002Fwebservices\u002Frest\u002Fsearch?query=EXT_ID:42174106&resultType=core&format=json","An evaluation of artificial intelligence assisted prostate biopsy reporting in the Articulate Pro study (abstract via Europe PMC)","npj Digital Medicine","2026-05-22",{"url":243,"title":244,"publisher":240,"date":241},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC13365413\u002F","An evaluation of artificial intelligence assisted prostate biopsy reporting in the Articulate Pro study",{"level":216,"checkedAt":171},"oxford-university-hospitals-articulate-pro-prostate-biopsy-ai",0,[249],{"kpi":36,"label":250,"unit":199,"aggregate":206,"higherIsBetter":206,"n":50,"nUpTo":247,"median":198,"min":198,"max":198,"byClaimant":251,"vendorOnly":182,"points":252},"Cycle time reduction",{"organization":50,"vendor":247,"regulator":247,"independent":247},[253],{"evidenceId":218,"organization":181,"value":198,"qualifier":200,"claimant":203,"grade":217,"pooled":206},{"low":255,"high":256},15000,270000,[258,275,303,320],{"slug":169,"title":259,"shortTitle":260,"definition":261,"status":9,"industries":262,"functions":263,"patterns":264,"audience":25,"autonomy":26,"adoptionStage":27,"evidenceCount":51,"publicEvidenceCount":51,"organizations":265,"bestGrade":217,"headline":269,"lastVerified":274,"indexable":206},"AI support for reading screening mammograms in breast cancer screening programs","Screening mammography reading","AI support for screening mammography scores every examination in a population based breast cancer screening program and either triages it to single or double reading or acts as decision support for the radiologists who read it. A radiologist still makes every recall decision.",[17],[19],[21,22],[266,267,268],"Capital Region of Denmark","German mammography screening program (PRAIM study sites)","Mammography screening programme in southwest Sweden (Malmö, Lund, Landskrona, Trelleborg)",{"kpi":38,"label":270,"unit":199,"n":271,"nUpTo":247,"kind":272,"value":273,"qualifier":200,"claimant":203,"organization":268,"vendorReported":182},"Productivity gain",2,"reported",44.2,"2026-11-12",{"slug":170,"title":276,"shortTitle":277,"definition":278,"status":9,"industries":279,"functions":280,"patterns":281,"audience":25,"autonomy":284,"adoptionStage":285,"segment":286,"evidenceCount":287,"publicEvidenceCount":287,"organizations":288,"bestGrade":217,"headline":301,"lastVerified":302,"indexable":206},"AI prioritization of radiology and imaging worklists","Radiology worklist triage","AI radiology worklist triage analyzes a medical image right after a scan and flags time sensitive findings, so the most urgent cases are read and acted on first. Examples include a brain bleed, a stroke causing large vessel occlusion or a pulmonary embolism. It reorders the radiologist's worklist and notifies the care team, and a radiologist confirms every finding before it changes a patient's treatment.",[17],[19],[21,282,283],"classification-and-routing","anomaly-detection","assist","mainstream","emergency and inpatient imaging",13,[289,290,291,292,293,294,295,296,297,268,298,299,300],"Adventist Health + Rideout","Isala","M42","Mercy","Ochsner Health","Seha Virtual Hospital (Saudi Ministry of Health)","Sheba Medical Center","Sidra Medicine","Singapore General Hospital (SGH)","Temple Health","UPMC Hamot","WellSpan Health",{"kpi":38,"label":270,"unit":199,"n":271,"nUpTo":247,"kind":272,"value":273,"qualifier":200,"claimant":203,"organization":268,"vendorReported":182},"2026-09-29",{"slug":304,"title":305,"shortTitle":306,"definition":307,"status":9,"industries":308,"functions":309,"patterns":310,"audience":25,"autonomy":311,"adoptionStage":27,"evidenceCount":51,"publicEvidenceCount":51,"organizations":312,"bestGrade":217,"headline":316,"lastVerified":171,"indexable":206},"diabetic-retinopathy-autonomous-screening","Autonomous AI screening for diabetic retinopathy at the point of care","Diabetic retinopathy screening","Autonomous AI screening for diabetic retinopathy reads retinal photographs taken in a primary care clinic or other point of care setting and returns a result, such as referable or not referable, without a specialist reading the image first. People with a positive or ungradable result are referred to an eye specialist.",[17],[19],[21,22],"supervised-agent",[313,314,315],"Johns Hopkins Medicine","Rajavithi Hospital","Tarzana Treatment Centers",{"kpi":317,"label":318,"unit":199,"n":271,"nUpTo":247,"kind":272,"value":319,"qualifier":200,"claimant":203,"organization":313,"vendorReported":182},"screening-completion-rate","Screening completion rate",100,{"slug":321,"title":322,"shortTitle":323,"definition":324,"status":9,"industries":325,"functions":326,"patterns":328,"audience":332,"autonomy":311,"adoptionStage":27,"evidenceCount":333,"publicEvidenceCount":287,"organizations":334,"bestGrade":217,"headline":347,"lastVerified":352,"indexable":206},"patient-appointment-scheduling-and-reminders-agent","AI agent for patient appointment scheduling, reminders and no show reduction","Patient scheduling and reminders","An AI agent for patient scheduling and reminders books, moves and cancels patient appointments by phone and messaging, and reminds and confirms patients. It follows the provider's scheduling rules (referral, triage level, clinician and visit type, preparation), confirms and reminds patients in two way conversations, predicts who is likely to miss an appointment, and offers freed slots to patients on the waiting list. Unlike a general branch booking or reminder agent, it writes into the electronic health record and must respect clinical constraints, so anything clinical goes to staff.",[17],[327,19],"customer-service",[329,330,22,331],"voice-agent","conversational-agent","agentic-workflow","customer-facing",16,[335,336,337,338,339,340,341,342,343,344,345,300,346],"Audibel","Emirates Health Services","Erasmus MC","Good Shepherd Rehabilitation Network","Howard Brown Health","Mid and South Essex NHS Foundation Trust","North Kansas City Hospital","Reid Health","Sheffield Children's NHS Foundation Trust","University Hospitals Coventry and Warwickshire NHS Trust","UMC Utrecht","Zuyderland Medisch Centrum",{"kpi":348,"label":349,"unit":199,"n":350,"nUpTo":247,"kind":351,"value":198,"qualifier":200,"claimant":219,"organization":219,"vendorReported":182},"no-show-reduction","No show reduction",5,"median","2026-09-27",{"indexable":206,"reasons":354},[],[356,360,365,371,378,385,393,400,407,414,421,428,434,440,446,452,459,466,472,478,483,488,495,500,506,513,518,523,530,535,541,548,553,559,565,570,576,581],{"id":127,"label":357,"issuer":133,"region":134,"url":135,"description":358,"useCases":359,"indexable":206,"hasGuide":206},"EU AI Act","Regulation (EU) 2024\u002F1689: risk based rules for AI systems, with obligations for high risk systems listed in Annex III and transparency duties under Article 50.",306,{"id":128,"label":361,"issuer":133,"region":134,"url":362,"description":363,"useCases":364,"indexable":206,"hasGuide":206},"GDPR","https:\u002F\u002Feur-lex.europa.eu\u002Feli\u002Freg\u002F2016\u002F679\u002Foj","General Data Protection Regulation, including Article 22 on decisions based solely on automated processing.",275,{"id":366,"label":367,"issuer":133,"region":134,"url":368,"description":369,"useCases":370,"indexable":206,"hasGuide":206},"dora","DORA","https:\u002F\u002Feur-lex.europa.eu\u002Feli\u002Freg\u002F2022\u002F2554\u002Foj","Digital Operational Resilience Act for financial entities: ICT risk, incident reporting and third party risk, including AI providers.",68,{"id":372,"label":373,"issuer":374,"region":144,"url":375,"description":376,"useCases":377,"indexable":206,"hasGuide":206},"iso-42001","ISO\u002FIEC 42001","ISO and IEC","https:\u002F\u002Fwww.iso.org\u002Fstandard\u002F81230.html","The international management system standard for AI.",146,{"id":379,"label":380,"issuer":381,"region":184,"url":382,"description":383,"useCases":384,"indexable":206,"hasGuide":206},"nist-ai-rmf","NIST AI Risk Management Framework","NIST","https:\u002F\u002Fwww.nist.gov\u002Fitl\u002Fai-risk-management-framework","Voluntary US framework to map, measure, manage and govern AI risk, with a generative AI profile.",114,{"id":386,"label":387,"issuer":388,"region":389,"url":390,"description":391,"useCases":392,"indexable":206,"hasGuide":206},"mas-ai-risk-management","MAS AI risk management guidelines","Monetary Authority of Singapore","asia-pacific","https:\u002F\u002Fwww.mas.gov.sg\u002Fregulation\u002Fguidelines\u002Fguidelines-on-artificial-intelligence-risk-management-for-financial-institutions","Singapore's supervisory expectations for AI risk management at financial institutions, issued in October 2026 and building on the FEAT principles.",35,{"id":394,"label":395,"issuer":396,"region":397,"url":398,"description":399,"useCases":247,"indexable":206,"hasGuide":206},"qcb-ai-guideline","QCB Artificial Intelligence Guideline","Qatar Central Bank","middle-east","https:\u002F\u002Fwww.qcb.gov.qa\u002FServices\u002FFinancial%20Technology\u002FQCB_Artificial_Intelligence_Guideline.pdf","Qatar Central Bank guideline for licensed financial institutions on governing, approving and monitoring AI systems, including outsourced ones.",{"id":401,"label":402,"issuer":403,"region":397,"url":404,"description":405,"useCases":406,"indexable":206,"hasGuide":206},"cbuae-ai-guidance","CBUAE guidance on AI and ML","Central Bank of the UAE","https:\u002F\u002Frulebook.centralbank.ae\u002Fen\u002Frulebook\u002Fguidance-note-consumer-protection-and-responsible-adoption-and-use-artificial-intelligence","UAE central bank expectations for the enabling technologies, AI and machine learning used by licensed financial institutions.",4,{"id":408,"label":409,"issuer":410,"region":134,"url":411,"description":412,"useCases":413,"indexable":206,"hasGuide":182},"uk-gdpr","UK GDPR","Information Commissioner's Office","https:\u002F\u002Fico.org.uk\u002Ffor-organisations\u002Fuk-gdpr-guidance-and-resources\u002F","The UK's version of the GDPR, including rules on solely automated decisions.",82,{"id":415,"label":416,"issuer":417,"region":134,"url":418,"description":419,"useCases":420,"indexable":206,"hasGuide":182},"uk-consumer-duty","FCA Consumer Duty","Financial Conduct Authority","https:\u002F\u002Fwww.fca.org.uk\u002Ffirms\u002Fconsumer-duty","UK rules that require firms to deliver good outcomes for retail customers, including through automated channels.",43,{"id":422,"label":423,"issuer":424,"region":389,"url":425,"description":426,"useCases":427,"indexable":206,"hasGuide":182},"apra-cps-230","APRA CPS 230","Australian Prudential Regulation Authority","https:\u002F\u002Fwww.apra.gov.au\u002Foperational-risk-management","Australian operational risk standard covering critical operations and material service providers.",26,{"id":429,"label":430,"issuer":133,"region":134,"url":431,"description":432,"useCases":433,"indexable":206,"hasGuide":182},"nis2","NIS2 Directive","https:\u002F\u002Feur-lex.europa.eu\u002Feli\u002Fdir\u002F2022\u002F2555\u002Foj","Directive (EU) 2022\u002F2555 on cybersecurity for essential and important entities, including telecom networks, energy and public administration.",23,{"id":129,"label":435,"issuer":436,"region":184,"url":437,"description":438,"useCases":439,"indexable":206,"hasGuide":182},"HIPAA","US Department of Health and Human Services","https:\u002F\u002Fwww.hhs.gov\u002Fhipaa\u002Findex.html","US rules for the privacy and security of protected health information.",22,{"id":441,"label":442,"issuer":443,"region":144,"url":444,"description":445,"useCases":64,"indexable":206,"hasGuide":182},"pci-dss","PCI DSS","PCI Security Standards Council","https:\u002F\u002Fwww.pcisecuritystandards.org\u002F","Security standard for any system that stores, processes or transmits cardholder data.",{"id":447,"label":448,"issuer":449,"region":184,"url":450,"description":451,"useCases":64,"indexable":206,"hasGuide":182},"us-sr-11-7","SR 26-2 model risk management","Federal Reserve, OCC and FDIC","https:\u002F\u002Fwww.federalreserve.gov\u002Fsupervisionreg\u002Fsrletters\u002FSR2602.htm","US supervisory guidance on model risk management that replaced SR 11-7 in April 2026, most relevant to banks with over $30 billion in assets. It covers quantitative models and non generative AI; generative and agentic AI models are outside its scope.",{"id":453,"label":454,"issuer":455,"region":134,"url":456,"description":457,"useCases":458,"indexable":206,"hasGuide":182},"uk-atrs","UK Algorithmic Transparency Recording Standard","UK Government","https:\u002F\u002Fwww.gov.uk\u002Fgovernment\u002Fcollections\u002Falgorithmic-transparency-recording-standard-hub","Mandatory transparency records for algorithmic tools used by UK central government.",18,{"id":460,"label":461,"issuer":462,"region":184,"url":463,"description":464,"useCases":465,"indexable":206,"hasGuide":182},"us-tcpa","Telephone Consumer Protection Act","Federal Communications Commission","https:\u002F\u002Fwww.fcc.gov\u002Fconsumers\u002Fguides\u002Fstop-unwanted-robocalls-and-texts","US consent rules for automated and prerecorded calls and texts; the FCC has confirmed AI generated voices count as artificial voices.",15,{"id":467,"label":468,"issuer":133,"region":134,"url":469,"description":470,"useCases":471,"indexable":206,"hasGuide":182},"eu-accessibility-act","European Accessibility Act","https:\u002F\u002Feur-lex.europa.eu\u002Feli\u002Fdir\u002F2019\u002F882\u002Foj","Directive (EU) 2019\u002F882: accessibility requirements for banking services, ecommerce and other digital services, applicable since June 2025.",14,{"id":473,"label":474,"issuer":475,"region":144,"url":476,"description":477,"useCases":471,"indexable":206,"hasGuide":182},"fatf-recommendations","FATF Recommendations","Financial Action Task Force","https:\u002F\u002Fwww.fatf-gafi.org\u002Fen\u002Fpublications\u002FFatfrecommendations\u002FFatf-recommendations.html","Global standards for anti money laundering and counter terrorist financing that national rules implement.",{"id":479,"label":480,"issuer":133,"region":134,"url":481,"description":482,"useCases":471,"indexable":206,"hasGuide":182},"solvency-ii","Solvency II","https:\u002F\u002Feur-lex.europa.eu\u002Feli\u002Fdir\u002F2009\u002F138\u002Foj","Directive 2009\u002F138\u002FEC: risk based capital, governance and model requirements for insurers.",{"id":484,"label":485,"issuer":133,"region":134,"url":486,"description":487,"useCases":287,"indexable":206,"hasGuide":182},"eu-amlr","EU Anti Money Laundering Regulation","https:\u002F\u002Feur-lex.europa.eu\u002Feli\u002Freg\u002F2024\u002F1624\u002Foj","Regulation (EU) 2024\u002F1624: the single EU rulebook for customer due diligence, beneficial ownership and suspicious transaction reporting.",{"id":489,"label":490,"issuer":491,"region":184,"url":492,"description":493,"useCases":494,"indexable":206,"hasGuide":182},"us-bsa","Bank Secrecy Act","FinCEN","https:\u002F\u002Fwww.fincen.gov\u002Fresources\u002Fstatutes-and-regulations\u002Fbank-secrecy-act","US anti money laundering law: customer due diligence, suspicious activity reports and record keeping.",12,{"id":496,"label":497,"issuer":133,"region":134,"url":498,"description":499,"useCases":494,"indexable":206,"hasGuide":182},"eu-psd2","PSD2","https:\u002F\u002Feur-lex.europa.eu\u002Feli\u002Fdir\u002F2015\u002F2366\u002Foj","Payment Services Directive 2: strong customer authentication, transaction risk analysis exemptions and open banking access.",{"id":501,"label":502,"issuer":503,"region":144,"url":504,"description":505,"useCases":494,"indexable":206,"hasGuide":182},"telecom-consumer-rules","Telecom consumer protection rules","National telecom regulators","https:\u002F\u002Fwww.berec.europa.eu\u002F","National rules on telecom contracts, switching, billing disputes and marketing consent.",{"id":507,"label":508,"issuer":509,"region":184,"url":510,"description":511,"useCases":512,"indexable":206,"hasGuide":182},"us-ecoa-reg-b","ECOA and Regulation B","Consumer Financial Protection Bureau","https:\u002F\u002Fwww.consumerfinance.gov\u002Frules-policy\u002Fregulations\u002F1002\u002F9\u002F","US fair lending rules, including specific reasons in adverse action notices, which also apply when credit decisions use AI models.",10,{"id":514,"label":515,"issuer":133,"region":134,"url":516,"description":517,"useCases":512,"indexable":206,"hasGuide":182},"eecc","European Electronic Communications Code","https:\u002F\u002Feur-lex.europa.eu\u002Feli\u002Fdir\u002F2018\u002F1972\u002Foj","Directive (EU) 2018\u002F1972: consumer protection, contract, switching and security rules for telecom operators.",{"id":519,"label":520,"issuer":133,"region":134,"url":521,"description":522,"useCases":512,"indexable":206,"hasGuide":182},"mifid-ii","MiFID II","https:\u002F\u002Feur-lex.europa.eu\u002Feli\u002Fdir\u002F2014\u002F65\u002Foj","Directive 2014\u002F65\u002FEU on markets in financial instruments: suitability and appropriateness of advice, record keeping and product governance.",{"id":524,"label":525,"issuer":526,"region":134,"url":527,"description":528,"useCases":529,"indexable":206,"hasGuide":182},"eba-loan-origination","EBA Guidelines on loan origination and monitoring","European Banking Authority","https:\u002F\u002Fwww.eba.europa.eu\u002Fregulation-and-policy\u002Fcredit-risk\u002Fguidelines-on-loan-origination-and-monitoring","Expectations for credit decisioning, including the use of automated models.",9,{"id":531,"label":532,"issuer":388,"region":389,"url":533,"description":534,"useCases":529,"indexable":206,"hasGuide":182},"mas-notice-626","MAS Notice 626","https:\u002F\u002Fwww.mas.gov.sg\u002Fregulation\u002Fnotices\u002Fnotice-626","Singapore's anti money laundering and counter terrorism financing requirements for banks.",{"id":536,"label":537,"issuer":133,"region":134,"url":538,"description":539,"useCases":540,"indexable":206,"hasGuide":182},"eu-idd","Insurance Distribution Directive","https:\u002F\u002Feur-lex.europa.eu\u002Feli\u002Fdir\u002F2016\u002F97\u002Foj","Directive (EU) 2016\u002F97: conduct rules for selling insurance, including demands and needs testing and advice.",8,{"id":542,"label":543,"issuer":544,"region":184,"url":545,"description":546,"useCases":547,"indexable":206,"hasGuide":182},"us-fcra","Fair Credit Reporting Act","Federal Trade Commission","https:\u002F\u002Fwww.ftc.gov\u002Flegal-library\u002Fbrowse\u002Fstatutes\u002Ffair-credit-reporting-act","US rules on consumer reports, their accuracy and permissible use, relevant to credit scoring and screening.",7,{"id":549,"label":550,"issuer":133,"region":134,"url":551,"description":552,"useCases":350,"indexable":206,"hasGuide":182},"eu-mortgage-credit-directive","EU Mortgage Credit Directive","https:\u002F\u002Feur-lex.europa.eu\u002Feli\u002Fdir\u002F2014\u002F17\u002Foj","Directive 2014\u002F17\u002FEU: creditworthiness assessment, disclosure and advice rules for residential mortgage lending.",{"id":554,"label":555,"issuer":556,"region":134,"url":557,"description":558,"useCases":350,"indexable":206,"hasGuide":182},"uk-psr-app-reimbursement","UK APP scam reimbursement rules","Payment Systems Regulator","https:\u002F\u002Fwww.psr.org.uk\u002Four-work\u002Fapp-scams\u002F","Mandatory reimbursement of authorised push payment scam victims by UK payment firms, which shifts scam losses onto banks.",{"id":560,"label":561,"issuer":562,"region":389,"url":563,"description":564,"useCases":406,"indexable":206,"hasGuide":182},"au-scams-prevention-framework","Australian Scams Prevention Framework","Australian Treasury","https:\u002F\u002Ftreasury.gov.au\u002Fconsultation\u002Fc2024-573813","Economy wide obligations for banks, telcos and digital platforms to prevent, detect, disrupt and respond to scams.",{"id":566,"label":567,"issuer":388,"region":389,"url":568,"description":569,"useCases":406,"indexable":206,"hasGuide":182},"mas-shared-responsibility-framework","MAS Shared Responsibility Framework","https:\u002F\u002Fwww.mas.gov.sg\u002Fregulation\u002Fguidelines\u002Fguidelines-on-shared-responsibility-framework","Singapore's framework that assigns banks and telcos duties and loss sharing for phishing scams.",{"id":571,"label":572,"issuer":573,"region":134,"url":574,"description":575,"useCases":406,"indexable":206,"hasGuide":182},"pra-ss1-23","PRA SS1\u002F23 model risk management","Prudential Regulation Authority","https:\u002F\u002Fwww.bankofengland.co.uk\u002Fprudential-regulation\u002Fpublication\u002F2023\u002Fmay\u002Fmodel-risk-management-principles-for-banks-ss","UK model risk management principles for banks, covering AI and machine learning models.",{"id":577,"label":578,"issuer":133,"region":134,"url":579,"description":580,"useCases":51,"indexable":206,"hasGuide":182},"eu-mar","EU Market Abuse Regulation","https:\u002F\u002Feur-lex.europa.eu\u002Feli\u002Freg\u002F2014\u002F596\u002Foj","Regulation (EU) 596\u002F2014: insider dealing and market manipulation, including the duty to detect and report suspicious orders and transactions.",{"id":582,"label":583,"issuer":584,"region":184,"url":585,"description":586,"useCases":51,"indexable":206,"hasGuide":182},"nyc-local-law-144","NYC Local Law 144","New York City","https:\u002F\u002Fwww.nyc.gov\u002Fsite\u002Fdca\u002Fabout\u002Fautomated-employment-decision-tools.page","Bias audits and notices for automated employment decision tools used in hiring and promotion in New York City.",1795077016804]